ARIXA PHARMACEUTICALS INC has a total of 35 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CARDIOXYL PHARMACEUTICALS INC, PARTHASARADHI REDDY BANDI and BOCHER DOMINIQUE.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 3 | |
#4 | Canada | 3 | |
#5 | Brazil | 2 | |
#6 | China | 2 | |
#7 | EPO (European Patent Office) | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Singapore | 2 | |
#10 | Israel | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Freund John | 27 |
#2 | Gordon Eric M | 22 |
#3 | Duncton Matthew A J | 11 |
#4 | Gallop Mark A | 10 |
#5 | Duncton Matthew Alexander James | 10 |
#6 | Duncton Matthew | 6 |
#7 | Gordon Eric | 6 |
#8 | John Freund | 2 |
#9 | Gallop Mark | 2 |
#10 | Sable Carole | 2 |
Publication | Filing date | Title |
---|---|---|
US2021060033A1 | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections | |
WO2020219258A1 | Methods of synthesizing aztreonam derivatives | |
US2020291022A1 | Crystalline form of an avibactam derivative | |
CA3114618A1 | Derivatives of relebactam and uses thereof | |
CA3077474A1 | Aztreonam derivatives and uses thereof | |
US10085999B1 | Beta-lactamase inhibitors and uses thereof | |
US2018148439A1 | Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams |